Children versus adults: pharmacokinetic and adverse-effect differences (Q34680689)

3 August 2017

1 reference

title

Children versus adults: pharmacokinetic and adverse-effect differences (English)

1 reference

3 August 2017

1 reference

Gail D Anderson

1

1 reference

3 August 2017

1 January 2002

1 reference

3 August 2017

1 reference

3 August 2017

43 Suppl 3

1 reference

3 August 2017

53-59

1 reference

Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide

3 August 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.43.S.3.5.X

Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.43.S.3.5.X

Clinical pharmacokinetics in newborns and infants. Age-related differences and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.43.S.3.5.X

Phenobarbital and diphenylhydantoin levels inneonates with seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.43.S.3.5.X

Clinical Pharmacokinetics of Diazepam

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.43.S.3.5.X

Pharmacokinetics of lorazepam in critically ill neonates with seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.43.S.3.5.X

The human hepatic cytochromes P450 involved in drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.43.S.3.5.X

Developmental Aspects of Drug Conjugation, with Special Reference to Glucuronidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.43.S.3.5.X

A study of conjugation and drug elimination in the human neonate

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.43.S.3.5.X

Enhanced hepatic drug clearance in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.43.S.3.5.X

Single-dose pharmacokinetics of lamotrigine in children: influence of age and antiepileptic comedication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.43.S.3.5.X

Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.43.S.3.5.X

The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert's syndrome).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.43.S.3.5.X

Lamotrigine-associated rash: risk/benefit considerations in adults and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.43.S.3.5.X

Metabolism of Lamotrigine to a Reactive Arene Oxide Intermediate

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.43.S.3.5.X

Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.43.S.3.5.X

The tolerability of lamotrigine in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.43.S.3.5.X

Bidirectional interaction of valproate and lamotrigine in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.43.S.3.5.X

Valproate-associated hepatotoxicity and its biochemical mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.43.S.3.5.X

Valproic acid hepatic fatalities: a retrospective review

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.43.S.3.5.X

Valproic acid hepatic fatalities. III. U.S. experience since 1986.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.43.S.3.5.X

Severe hepatotoxicity during valproate therapy: an update and report of eight new fatalities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.43.S.3.5.X

Valproic acid hepatic fatalities. II. US experience since 1984.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.43.S.3.5.X

Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.43.S.3.5.X

Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.43.S.3.5.X

Medium chain acyl-CoA dehydrogenase deficiency and fatal valproate toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.43.S.3.5.X

Early childhood hepatocerebral degeneration misdiagnosed as valproate hepatotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.43.S.3.5.X

Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.43.S.3.5.X

Sodium valproate acutely inhibits lamotrigine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1528-1157.43.S.3.5.X

10.1046/J.1528-1157.43.S.3.5.X

21 January 2018

Identifiers

DOI

1 reference

release_d7nuwyp75nagdkoa3x5oi5zipu

3 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/d7nuwyp75nagdkoa3x5oi5zipu

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

12060006

1 reference

PubMed ID

12060006